<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DIPHENHYDRAMINE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(dye-fen-hye'dra-meen)<br/><span class="topboxtradename">Allerdryl <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Banophen, </span><span class="topboxtradename">Belix, </span><span class="topboxtradename">Ben-Allergin, </span><span class="topboxtradename">Bena-D, </span><span class="topboxtradename">Benadryl, </span><span class="topboxtradename">Benadryl Dye-Free, </span><span class="topboxtradename">Benahist, </span><span class="topboxtradename">Benoject, </span><span class="topboxtradename">Benylin, </span><span class="topboxtradename">Compoz, </span><span class="topboxtradename">Diahist, </span><span class="topboxtradename">Dihydrex, </span><span class="topboxtradename">Diphen, </span><span class="topboxtradename">Diphenacen-50, </span><span class="topboxtradename">Fenylhist, </span><span class="topboxtradename">Hyrexin, </span><span class="topboxtradename">Insomnal, </span><span class="topboxtradename">Nordryl, </span><span class="topboxtradename">Nytol with DPH, </span><span class="topboxtradename">Sleep-Eze 3, </span><span class="topboxtradename">Sominex Formula 2, </span><span class="topboxtradename">Tusstat, </span><span class="topboxtradename">Twilite, </span><span class="topboxtradename">Valdrene, </span><span class="topboxtradename">Wehdryl<br/></span><b>Classifications:</b> <span class="classification">antihistamine</span>; <span class="classification">h<sub>1</sub>-receptor antagonist</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg capsules, tablets; 6.25 mg/5 mL, 12.5 mg/5 mL syrup; 50 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>H<sub>1</sub>-receptor antagonist and antihistamine with significant anticholinergic activity. High incidence of drowsiness, but GI side
         effects are minor. Effects in parkinsonism and drug-induced extrapyramidal symptoms are apparently related to its ability
         to suppress central cholinergic activity and to prolong action of dopamine by inhibiting its reuptake and storage.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Competes for H<sub>1</sub>-receptor sites on effector cells, thus blocking histamine release.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Temporary symptomatic relief of various allergic conditions and to treat or prevent motion sickness, vertigo, and reactions
         to blood or plasma in susceptible patients. Also used in anaphylaxis as adjunct to epinephrine and other standard measures
         after acute symptoms have been controlled; in treatment of parkinsonism and drug-induced extrapyramidal reactions; as a nonnarcotic
         cough suppressant; as a sedative-hypnotic; and for treatment of intractable insomnia.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to antihistamines of similar structure; lower respiratory tract symptoms (including acute asthma); narrow-angle
         glaucoma; prostatic hypertrophy, bladder neck obstruction; GI obstruction or stenosis; pregnancy (category C), lactation,
         premature neonates, and neonates; use as nighttime sleep aid in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of asthma; convulsive disorders; increased IOP; hyperthyroidism; hypertension, cardiovascular disease; diabetes mellitus;
         older adults, infants, and young children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Allergy Symptoms, Antiparkinsonism, Motion Sickness, Nighttime Sedation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2550 mg t.i.d. or q.i.d. (max: 300 mg/d) <span class="rdroute">IV/IM</span> 1050 mg q46h (max: 400 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV/IM</span>
<i>26 y</i>, 6.25 mg q46h (max: 300 mg/24 h); <i>612 y</i>, 12.525 mg q46h (max: 300 mg/24 h)<br/><br/><span class="indicationtitle">Nonproductive Cough</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 25 mg q46h (max: 100 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>26 y</i>, 6.25 mg q46h (max: 25 mg/24 h); <i>612 y</i>, 12.5 mg q46h (max: 50 mg/24 h)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or milk to lessen GI adverse effects.</li>
<li>For motion sickness: Give the first dose 30 min before exposure to motion; give remaining doses before meals and at bedtime.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give IM injection deep into large muscle mass; alternate injection sites. Avoid perivascular or SC injections because of its
            irritating effects.
         </li>
<li>
            				Note: Hypersensitivity reactions (including anaphylactic shock) are more likely to occur with parenteral than PO administration.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Give at a rate of 25 mg or a fraction thereof over 1 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span>
<b>Furosemide.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store in tightly covered containers at 15°30° C (59°86° F) unless otherwise directed by manufacturer.
            Keep injection and elixir formulations in light-resistant containers.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness,</span> dizziness, headache, fatigue, disturbed coordination, tingling, heaviness and weakness of hands, tremors, euphoria, nervousness,
      restlessness, insomnia; confusion; (especially in children): excitement, fever. <span class="typehead">CV:</span> Palpitation, <span class="speceff-common">tachycardia,</span> mild hypotension or hypertension, <span class="speceff-life">cardiovascular collapse</span>. <span class="typehead">Special Senses:</span> Tinnitus, vertigo, dry nose, throat, nasal stuffiness; blurred vision, diplopia, photosensitivity, dry eyes. <span class="typehead">GI:</span>
<span class="speceff-common">Dry mouth,</span> nausea, epigastric distress, anorexia, vomiting, constipation, or diarrhea. <span class="typehead">Urogenital:</span> Urinary frequency or retention, dysuria. <span class="typehead">Body as a Whole:</span> Hypersensitivity (skin rash, urticaria, photosensitivity, <span class="speceff-life">anaphylactic shock</span>). <span class="typehead">Respiratory:</span> Thickened bronchial secretions, wheezing, sensation of chest tightness. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>In common with other antihistamines, diphenhydramine should be discontinued 4 d prior to <span class="alt">skin testing</span> procedures for allergy because it may obscure otherwise positive reactions.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span>, <span class="classification">mao inhibitors</span> compound CNS depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract but only 4060% reaches systemic circulation. <span class="typehead">Onset:</span> 1530 min. <span class="typehead">Peak:</span> 14 h. <span class="typehead">Duration:</span> 47 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead"> Metabolism:</span> Metabolized in liver; some degradation in lung and kidney. <span class="typehead">Elimination:</span> Mostly excreted in urine within 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiovascular status especially with pre-existing cardiovascular disease.</li>
<li>Monitor for adverse effects especially in children and the older adult.</li>
<li>Supervise ambulation and use side-rails as necessary. Drowsiness is most prominent during the first few days of therapy and
            often disappears with continued therapy. Older adults are especially likely to manifest dizziness, sedation, and hypotension.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not use alcohol and other CNS depressants because of the possible additive CNS depressant effects with concurrent use.</li>
<li>Do not drive or engage in other potentially hazardous activities until the response to drug is known.</li>
<li>Increase fluid intake, if not contraindicated; drug has an atropine-like drying effect (thickens bronchial secretions) that
            may make expectoration difficult.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>